News und Analysen

Rocket Lab (NASDAQ: RKLB) stock rocketed to a 10th straight day of gains Friday, surging 5.7% through 11:15 a.m. ET after announcing the New Zealand-based space company announced yet another big

There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, Pfizer

The leading pipeline drug being developed by Cidara Therapeutics (NASDAQ: CDTX) got a real boost from a regulator on Thursday, and the biotech's share price moved accordingly. Cidara's stock closed

Shares in Viking Therapeutics (NASDAQ: VKTX) were up more than 16% in the week to Thursday at 1 pm. The move comes after the announcement of another acquisition of a small-cap biopharmaceutical

In today's video, I discuss recent updates impacting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and CoreWeave (NASDAQ: CRWV). To learn more, check out the short video, consider

Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday.

According to a filing

Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 billion. It has been soaring in recent years due to the success of its highly

Do you want to invest in some underrated artificial intelligence (AI) stocks? The ones that are listed here may be intriguing options because while they might seem expensive at first glance, they

Advanced Micro Devices Inc (NASDAQ: AMD) closed at $235.56, up 11.37%. Trading volume reached 154 million shares, roughly 3 times its three-month average of 58 million. The stock hit a new 52-week

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices

Megacap technology stocks are starting to look a little expensive, especially after recent moves in stocks like Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). It's tough to know

Any pharmaceutical company as large and sprawling as AbbVie (NYSE: ABBV) never stops being busy, from pushing investigational drugs along the development pipeline to shipping blockbuster medications

Shares of Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set

Pfizer (NYSE: PFE) has a huge 6.3% dividend yield. That's actually a lot lower than it was not too long ago, thanks to a large stock advance in recent days based on news. But Pfizer's price rebound

If x is good, isn't 2x even better? Usually. Granted, there can be too much of a good thing. For example, you might regret eating two giant helpings of ice cream rather than one. However, in many

Nvidia is arguably the king of Wall Street these days. As the maker of high-performing graphics processing units (GPUs) that power artificial intelligence (AI) programs and large language models

Summit Financial Wealth Advisors, LLC initiated a new position in First Trust Enhanced Short Maturity ETF (NASDAQ:FTSM), acquiring approximately $20.03 million in shares as of Q3 2025, according to

In this video, I will discuss recent updates regarding Advanced Micro Devices (NASDAQ: AMD) and OpenAI. Watch the short video to learn more, consider subscribing, and click the special offer link

Pfizer (NYSE: PFE) made a deal with the White House to avoid paying tariffs on imported products.

*Stock prices used were the afternoon prices of Oct. 3, 2025. The video was published on Oct. 5

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The

Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good